Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status-Reference-Cited by-同舟云学术

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Published:2019-08-12 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Gijtenbeek Rolof GP¹,de Jong Kim²,Venmans Ben JW¹,van Vollenhoven Femke HM¹,Ten Brinke Anneke¹,Van der Wekken Anthonie J³,van Geffen Wouter H¹

Affiliation:

1. Medical Center Leeuwarden; Department of Pulmonary Diseases; Henri Dunantweg 2 Leeuwarden Netherlands

2. Medical Center Leeuwarden; Department of Epidemiology; Henri Dunantweg 2 Leeuwarden Friesland Netherlands

3. University of Groningen, University Medical Center Groningen; Department of Pulmonary Diseases; Hanzeplein 1 Groningen Netherlands

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013382/epdf/full

Reference28 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer;Borghaei;New England Journal of Medicine,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non small-cell lung cancer;Brahmer;New England Journal of Medicine,2015

3. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution;Buccheri;European Journal of Cancer,1996

4. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature;D'Addario;Journal of Clinical Oncology,2005

5. Trends in treatment and relative survival among non-small cell lung cancer patients in the Netherlands (1990-2014): disparities between younger and older patients;Driessen;Lung Cancer,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status;Cochrane Database of Systematic Reviews;2023-07-07